Notice: This company has been marked as potentially delisted and may not be actively trading. Amedica (AMDA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends AMDA vs. CATX, INFU, SGHT, ARAY, PROF, SKIN, NVRO, BWAY, KRMD, and DRTSShould you be buying Amedica stock or one of its competitors? The main competitors of Amedica include Perspective Therapeutics (CATX), InfuSystem (INFU), Sight Sciences (SGHT), Accuray (ARAY), Profound Medical (PROF), Beauty Health (SKIN), Nevro (NVRO), BrainsWay (BWAY), KORU Medical Systems (KRMD), and Alpha Tau Medical (DRTS). These companies are all part of the "medical" sector. Amedica vs. Perspective Therapeutics InfuSystem Sight Sciences Accuray Profound Medical Beauty Health Nevro BrainsWay KORU Medical Systems Alpha Tau Medical Perspective Therapeutics (NYSE:CATX) and Amedica (NASDAQ:AMDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation. Which has higher earnings & valuation, CATX or AMDA? Amedica has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerspective Therapeutics$1.43M142.27-$46.51MN/AN/AAmedica$11.23M4.55-$9.32M-$3.13-1.37 Which has more risk and volatility, CATX or AMDA? Perspective Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Amedica has a beta of -1.24, indicating that its share price is 224% less volatile than the S&P 500. Is CATX or AMDA more profitable? Amedica has a net margin of -139.62% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Amedica's return on equity.Company Net Margins Return on Equity Return on Assets Perspective Therapeutics-4,096.66% -27.40% -23.16% Amedica -139.62%-148.60%-67.83% Do analysts recommend CATX or AMDA? Perspective Therapeutics currently has a consensus price target of $21.57, suggesting a potential upside of 616.66%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Amedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perspective Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Amedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CATX or AMDA? In the previous week, Perspective Therapeutics had 11 more articles in the media than Amedica. MarketBeat recorded 11 mentions for Perspective Therapeutics and 0 mentions for Amedica. Perspective Therapeutics' average media sentiment score of 0.78 beat Amedica's score of 0.00 indicating that Perspective Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Perspective Therapeutics Positive Amedica Neutral Do institutionals & insiders hold more shares of CATX or AMDA? 54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 3.7% of Amedica shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Comparatively, 0.9% of Amedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CATX or AMDA? Amedica received 291 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Perspective Therapeutics an outperform vote while only 64.90% of users gave Amedica an outperform vote. CompanyUnderperformOutperformPerspective TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesAmedicaOutperform Votes30764.90% Underperform Votes16635.10% SummaryPerspective Therapeutics beats Amedica on 12 of the 16 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Amedica News Delivered to You Automatically Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMDA vs. The Competition Export to ExcelMetricAmedicaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.04M$4.48B$5.09B$8.84BDividend YieldN/A36.79%5.04%4.07%P/E Ratio-1.1916.09101.4814.96Price / Sales4.5543.701,207.9887.23Price / CashN/A52.2739.7136.27Price / Book2.395.806.936.35Net Income-$9.32M$13.76M$118.81M$225.93M Amedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMDAAmedicaN/A$4.30+15.6%N/A+646.4%$51.04M$11.23M-1.37N/AGap UpCATXPerspective Therapeutics3.1773 of 5 stars$3.01-51.2%$21.57+616.7%N/A$203.45M$1.43M0.00116Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeINFUInfuSystem1.7054 of 5 stars$9.19+1.9%$13.00+41.5%N/A$195.38M$125.79M151.67499SGHTSight Sciences2.5293 of 5 stars$3.76+0.8%$5.50+46.3%+63.6%$190.86M$81.06M-3.69210ARAYAccuray4.7052 of 5 stars$1.89+2.7%$9.00+377.5%-32.5%$189.57M$446.55M-10.94987Analyst RevisionPROFProfound Medical2.4674 of 5 stars$7.52-2.2%$13.75+82.8%-31.2%$185.44M$7.20M0.00150SKINBeauty Health2.9718 of 5 stars$1.40-6.1%$2.55+82.8%-36.3%$173.01M$398M-3.321,030Analyst RevisionPositive NewsNVRONevro2.8971 of 5 stars$4.43+4.7%$9.10+105.2%-74.5%$166.16M$425.17M-2.241,215Analyst UpgradeBWAYBrainsWay4.195 of 5 stars$9.84+0.1%$13.17+33.8%+103.9%$164.13M$31.78M98.31120KRMDKORU Medical Systems2.0562 of 5 stars$3.58-1.9%$4.13+15.2%+60.1%$164.11M$28.52M0.0080DRTSAlpha Tau Medical2.4016 of 5 stars$2.30flat$8.00+248.6%-20.7%$159.89MN/A0.0080 Related Companies and Tools Related Companies Perspective Therapeutics Competitors InfuSystem Competitors Sight Sciences Competitors Accuray Competitors Profound Medical Competitors Beauty Health Competitors Nevro Competitors BrainsWay Competitors KORU Medical Systems Competitors Alpha Tau Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMDA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedica Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMDA Stock Alerts